the benefits of glp-1 drugs beyond obesity Can one drug do it all? Reviewing expanding clinical universe agonists GLP-1 Medications Beyond Weight Loss
Description
J.CapehornM.CharpentierG.DottaF.HenkelE.LingvayI.et al (2018)
Even among patients with diabetes, where the clinical case for continued treatment was strongest, 46.5 percent stopped within 12 months
Balkrishna Chaube, Yale University, United States
Histological resolution of MASH without fibrosis worsening - the studys primary outcome - occurred in 39% of liraglutide recipients vs
